In the field of infectious disease drug development, preclinical research plays a critical role in evaluating the safety, efficacy, and pharmacological properties of potential drug candidates before they progress to human clinical trials. Our company is a leading provider of preclinical research services, specializing in infectious disease therapy development.
Overview of Preclinical Research
Preclinical research consists of a series of rigorous laboratory investigations that precede human clinical trials. This crucial phase involves evaluating drug candidates in non-human subjects to examine their pharmacokinetic and pharmacodynamic properties, as well as potential toxicities. The paramount objective of preclinical research is to gather comprehensive data that substantiates the safe and effective utilization of a drug in human subjects.
- Pharmacological Studies
In vitro pharmacological studies involve conducting experiments in a controlled laboratory setting, using isolated cells, tissues, or biochemical systems. In vivo pharmacological studies involve investigating the effects of a drug candidate within a living organism, typically an animal model. By administering the drug to animals and closely monitoring their physiological responses, researchers can gather valuable data on the drug's efficacy, dosage range, and potential side effects.
- Pharmacokinetic Analysis
Pharmacokinetic analysis focuses on understanding how the body processes a drug candidate, encompassing its absorption, distribution, metabolism, and excretion (ADME). This analysis provides crucial information about the drug's behavior in the body, its bioavailability, and its potential for accumulation or elimination.
- Drug Safety Evaluation
Preclinical drug safety evaluation is a critical aspect of preclinical research, aiming to identify, assess, and mitigate any potential risks associated with the use of a drug candidate. This comprehensive evaluation involves a series of tests and analyses to understand the drug's safety profile, potential toxic effects, and any adverse reactions it may induce.
Fig.1 Common types of disease models. (Sajjad H., et al., 2021)
Infectious diseases pose significant global health challenges, and the development of effective therapies is crucial. Preclinical research plays a vital role in identifying and advancing potential drug candidates for infectious disease therapy development. It allows for the early identification of promising compounds, optimization of dosages, and assessment of potential adverse effects. We can provide preclinical research services for the following types of infectious disease therapeutics. If you are interested, you can click on the link below to learn more.
Our Services
Our company understands the unique complexities of infectious disease therapy development. We have a dedicated team of experts with extensive experience in infectious disease preclinical research. Our scientists employ a multidisciplinary approach, combining in vivo and in vitro studies, to provide comprehensive data on the safety and efficacy of potential drug candidates, thereby advancing our therapeutic development solutions.
Pharmacodynamics
- In Vivo Efficacy Models
-Pathogen Infection Model Development
-Genetically Engineering Model Development
-Humanized Model Development
-Customized Animal Model Development
- Activity Testing
- Drug Resistance Evaleation
Pharmacokinetics
- In Vitro Pharmacokinetics
-Physicochemical Studies
-Metabolism Studies
-Permeability and Transporter Studies
- In Vivo Pharmacokinetics
-Bioavailability
-Quantitative Tissue Distribution
-Metabolite Profiling and Identification
-Drug Excretion
Drug Safety Evaluation
- General Toxicology
- Genetic Toxicology
- Developmental and Reproductive Toxicity
- Immunogenicity and Immunotoxicity
- Local Toxicity
- Phototoxicity
- Tissue Cross-Reactivity
- Toxicokinetics
Preclinical research serves as a fundamental pillar in infectious disease drug discovery and development. With our expertise in infectious disease preclinical research, we aim to contribute to the development of safe and effective therapies. If our comprehensive suite of services has piqued your interest, we earnestly encourage you to reach out to us without any reservations.
References
- Sajjad H., et al. "Cancer models in preclinical research: A chronicle review of advancement in effective cancer research." Animal Models and Experimental Medicine 4.2 (2021): 87-103.
- Loewa Anna, James J. Feng, and Sarah Hedtrich. "Human disease models in drug development." Nature reviews bioengineering 1.8 (2023): 545-559.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
